Teva Pharmaceuticals (TEVA 2.00%) is often referred to as the biggest generic drugmaker in the world, and its 2.8% dividend yield can look attractive to investors seeking health care exposure in their portfolio. However, the company is facing many headwinds in the coming years. Its top-selling multiple sclerosis drug Copaxone, for instance, is not a generic product and is facing upcoming roadblocks that could stall the company's growth. In the following video, health care analyst Max Macaluso elaborates on the three biggest challenges Teva is facing today.
Teva's 3 Biggest Challenges
By Max Macaluso – Apr 26, 2013 at 6:30PM
NYSE: TEVA
Teva Pharmaceutical Industries
Market Cap
$28B
Today's Change
(-2.00%) $0.49
Current Price
$23.97
Price as of November 7, 2025 at 4:00 PM ET
Teva is one of the largest pharmaceutical companies in the world, but what roadblocks lie ahead?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo